Dalotuzumab
Dalotuzumab
Dalotuzumab (pronunciation: da-lo-tu-zu-mab) is a type of monoclonal antibody used in the field of oncology for the treatment of certain types of cancer.
Etymology
The name 'Dalotuzumab' is derived from the International Nonproprietary Names (INN), where 'mab' stands for monoclonal antibody, 'tu' signifies that the drug targets a tumor, and 'lo' indicates that the drug is humanized. The prefix 'Dalo' does not have a specific meaning and is used for easier identification of the drug.
Mechanism of Action
Dalotuzumab works by binding to the Insulin-like growth factor 1 receptor (IGF-1R), thereby inhibiting the growth and proliferation of cancer cells.
Related Terms
- Monoclonal Antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells.
- Oncology: The branch of medicine that deals with the prevention, diagnosis, and treatment of cancer.
- Insulin-like growth factor 1 receptor (IGF-1R): A protein found on the surface of human cells. It is a receptor that binds to a hormone called insulin-like growth factor 1.
Usage
Dalotuzumab is currently being studied in clinical trials for its effectiveness in treating various types of cancers, including colorectal cancer and breast cancer.
Side Effects
Like all medications, Dalotuzumab can cause side effects. Common side effects include fatigue, nausea, and rash. Severe side effects may include lung problems and allergic reactions.
See Also
External links
- Medical encyclopedia article on Dalotuzumab
- Wikipedia's article - Dalotuzumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski